Ben Auspitz is a partner with F-Prime Capital. A fellow venture capitalist has referred to him as the “best gene/cell therapy VC I can think of,” a testament to his expertise in pharmaceuticals and life science.
Before joining F-Prime Capital, he was the therapeutic area head for immuno-inflammatory products at CombinatoRx, where he managed the development of seven programmes from assay stage into phase II clinical studies. He also worked as a consultant with Braun Consulting and Vertex Partners.
He serves on the board of Indalo Therapeutics, Akrevia Therapeutics, Checkmate Pharmaceuticals, and Compass Therapeutics and serves as Chairman of Modis Therapeutics.
Ben has previously been involved with several companies that were acquired or went public, such as Symbiomix Therapeutics, Bikam Pharmaceuticals, Ligocyte Pharmaceuticals, Respivert, Dimension Therapeutics, Blueprint Medicine, Coherus Biosciences, REGENXBio, Unum Therapeutics, Precision Biosciences, Orchard Therapeutics, and Ultragenyx.
Ben received his bachelor’s at Harvard University.Tags: biotechnology, VC